IFNA1 and neoplasm: It has been hypothesized that the VSV-mediated expression of IFN-β would, therefore, not only improve the safety of VSV by restricting its replication to IFN-resistant tumor cells, but it could potentially enhance the efficacy of oncolytic VSV therapy through the induction of antitumor immune responses.